{"id":"W2147663823","doi":"10.1093/annonc/mdq651","title":"Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Onyx Pharmaceuticals; Canadian Centre for Applied Research in Cancer Control; Bayer HealthCare; Bayer","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Internal medicine; Rash; Oncology; Expanded access; Population; Adverse effect; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Hepatocellular carcinoma; Surgery; Phases of clinical research; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01064983,0.001391131,0.003534112,0.0003113387,0.0009808111,0.001918264,0.0007078761,0.001740711,0.003774802],"category_scores_gemma":[0.01018648,0.0005108967,0.002424936,0.000727366,0.001208847,0.001997155,0.0009565267,0.001882791,0.00097669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006753246,"about_ca_system_score_gemma":0.001205293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001363656,"about_ca_topic_score_gemma":0.002514654,"domain_scores_codex":[0.9926057,0.004823484,0.0004556572,0.0007950422,0.0007996724,0.0005204592],"domain_scores_gemma":[0.9925034,0.002869935,0.001142095,0.001440096,0.001064609,0.0009798146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8745677,0.01109292,0.04481937,0.0009570887,0.009229384,0.0003396797,0.0006309646,0.0006564247,0.008461787,0.0002877313,0.004792939,0.04416402],"study_design_scores_gemma":[0.4017419,0.1510934,0.4052159,0.0002634411,0.019787,0.0007601947,0.001038151,0.0009250431,0.005671006,0.001060456,0.01215144,0.0002920377],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824217,0.002429688,0.001777736,0.0003971171,0.000130686,0.002632797,0.00634414,0.00009748227,0.003768762],"genre_scores_gemma":[0.9891385,0.0004193821,0.0018248,0.0008004486,0.0001062059,0.00153079,0.004740602,0.00006411022,0.001375138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01064983,"threshold_uncertainty_score":0.05632234,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3243979502389615,"score_gpt":0.4237045269783182,"score_spread":0.09930657673935667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}